Universe Pharmaceuticals Inc. reported its financial results for the six months ended March 31, 2025. The company experienced a significant decrease in revenues, which fell by 29.0% to $9.2 million from $12.9 million in the same period the previous year. This decline in revenue was primarily attributed to a decrease in the average selling price and sales volume of the company's third-party products. The company also reported a net loss of $3.3 million, an increase of 37.4% from the net loss of $2.4 million recorded in the same period of 2024. The loss from operations was $2.3 million, up from $1.7 million in the prior year, due to reduced revenue and increased general and administrative expenses. There was no specific outlook or guidance provided in the report.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.